These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

476 related articles for article (PubMed ID: 30826965)

  • 1. PD-1/PD-L1 blockade in cervical cancer: current studies and perspectives.
    Wang Y; Li G
    Front Med; 2019 Aug; 13(4):438-450. PubMed ID: 30826965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A review of the PD-1/PD-L1 checkpoint in bladder cancer: From mediator of immune escape to target for treatment.
    Zhou TC; Sankin AI; Porcelli SA; Perlin DS; Schoenberg MP; Zang X
    Urol Oncol; 2017 Jan; 35(1):14-20. PubMed ID: 27816403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Challenges and potential of PD-1/PD-L1 checkpoint blockade immunotherapy for glioblastoma.
    Wang X; Guo G; Guan H; Yu Y; Lu J; Yu J
    J Exp Clin Cancer Res; 2019 Feb; 38(1):87. PubMed ID: 30777100
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Roles of Programmed Cell Death Ligand-1/ Programmed Cell Death-1 (PD-L1/PD-1) in HPV-induced Cervical Cancer and Potential for their Use in Blockade Therapy.
    Zhang L; Zhao Y; Tu Q; Xue X; Zhu X; Zhao KN
    Curr Med Chem; 2021; 28(5):893-909. PubMed ID: 32003657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD-1/PD-L1 blockade in cancer treatment: perspectives and issues.
    Hamanishi J; Mandai M; Matsumura N; Abiko K; Baba T; Konishi I
    Int J Clin Oncol; 2016 Jun; 21(3):462-73. PubMed ID: 26899259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blocking PD-1/PD-L1 in Genitourinary Malignancies: To Immunity and Beyond.
    Dallos MC; Drake CG
    Cancer J; 2018; 24(1):20-30. PubMed ID: 29360724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors.
    Hargadon KM; Johnson CE; Williams CJ
    Int Immunopharmacol; 2018 Sep; 62():29-39. PubMed ID: 29990692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Current events in immunotherapy for upper aerodigestive tract cancer].
    Outh-Gauer S; Le Tourneau C; Broudin C; Scotte F; Roussel H; Hans S; Mandavit M; Tartour E; Badoual C
    Ann Pathol; 2017 Feb; 37(1):79-89. PubMed ID: 28111039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD-1/PD-L1 and immunotherapy for pancreatic cancer.
    Feng M; Xiong G; Cao Z; Yang G; Zheng S; Song X; You L; Zheng L; Zhang T; Zhao Y
    Cancer Lett; 2017 Oct; 407():57-65. PubMed ID: 28826722
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas.
    Goodman A; Patel SP; Kurzrock R
    Nat Rev Clin Oncol; 2017 Apr; 14(4):203-220. PubMed ID: 27805626
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Balstilimab and other immunotherapy for recurrent and metastatic cervical cancer.
    Bose CK
    Med Oncol; 2022 Jan; 39(4):47. PubMed ID: 35092506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Progress and challenges of predictive biomarkers of anti PD-1/PD-L1 immunotherapy: A systematic review.
    Teng F; Meng X; Kong L; Yu J
    Cancer Lett; 2018 Feb; 414():166-173. PubMed ID: 29155348
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging Therapeutic Strategies of Different Immunotherapy Approaches Combined with PD-1/PD-L1 Blockade in Cervical Cancer.
    Ge Y; Zhang Y; Zhao KN; Zhu H
    Drug Des Devel Ther; 2022; 16():3055-3070. PubMed ID: 36110399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhancing cancer immunotherapy: Exploring strategies to target the PD-1/PD-L1 axis and analyzing the associated patent, regulatory, and clinical trial landscape.
    Kirthiga Devi SS; Singh S; Joga R; Patil SY; Meghana Devi V; Chetan Dushantrao S; Dwivedi F; Kumar G; Kumar Jindal D; Singh C; Dhamija I; Grover P; Kumar S
    Eur J Pharm Biopharm; 2024 Jul; 200():114323. PubMed ID: 38754524
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant checkpoint blockade for cancer immunotherapy.
    Topalian SL; Taube JM; Pardoll DM
    Science; 2020 Jan; 367(6477):. PubMed ID: 32001626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cancer immunotherapy and the PD-1/PD-L1 checkpoint pathway.
    Barclay J; Creswell J; León J
    Arch Esp Urol; 2018 May; 71(4):393-399. PubMed ID: 29745928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of programmed cell death-1 (PD-1) and its ligands in pediatric cancer.
    van Dam LS; de Zwart VM; Meyer-Wentrup FA
    Pediatr Blood Cancer; 2015 Feb; 62(2):190-197. PubMed ID: 25327979
    [TBL] [Abstract][Full Text] [Related]  

  • 19. IMMUNOTHERAPY TREATMENT AGAINST CERVICAL CANCER.
    Jiménez-Lima R; Arango-Bravo E; Galicia-Carmona T; Lino-Silva LS; Trejo-Durán GE; Alvarado-Silva C; Castañeda-Renderos OH; Vanoye-Carlo EG; Torre CF; Dueñas-González A; Cetina-Pérez L
    Rev Invest Clin; 2020; 72(4):231-238. PubMed ID: 33064705
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Programmed cell death protein-1 (PD-1)/programmed death-ligand-1 (PD-L1) axis in hepatocellular carcinoma: prognostic and therapeutic perspectives.
    Mocan T; Sparchez Z; Craciun R; Bora CN; Leucuta DC
    Clin Transl Oncol; 2019 Jun; 21(6):702-712. PubMed ID: 30387047
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.